Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Isaacs, John D ^a   Harari, Olivier ^b   Kobold, Uwe ^c   Lee, Janet S ^d   Bernasconi, Corrado ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; HAPTOGLOBIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; PLACEBO; TOCILIZUMAB; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANEMIA; ARTICLE; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BINDING CAPACITY; IRON METABOLISM; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ADULT; AGED; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; HAPTOGLOBINS; HEMOGLOBINS; HEPCIDINS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION;

EID: 84888590842     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4397     Document Type: Article

References (19)

1. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010, 116:3627-3634. 10.1182/blood-2010-03-271791, 20644113.
2. Cazzola M, Ponchio L, de Benedetti F, Ravelli A, Rosti V, Bequin Y, Invernizzi R, Barosi G, Martini A. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996, 87:4824-4830.
3. Masson C. Rheumatoid anemia. Joint Bone Spine 2011, 78:131-137. 10.1016/j.jbspin.2010.05.017, 20851655.
4. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093. 10.1126/science.1104742, 15514116.
5. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009, 46:387-393. 10.1053/j.seminhematol.2009.06.001, 2755591, 19786207.
6. Nielsen MJ, Moller HJ, Moestrup SK. Hemoglobin and heme scavenger receptors. Antioxid Redox Signal 2010, 12:261-273. 10.1089/ars.2009.2792, 19659436.
7. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005, 106:1864-1866. 10.1182/blood-2005-03-1159, 15886319.
8. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276. 398432, 15124018.
9. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005, 5:1731-1740. 10.1016/j.intimp.2005.05.010, 16102523.
10. Hashizume M, Uchiyama Y, Horai N, Tomosugi N, Mihara M. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int 2010, 30:917-923. 10.1007/s00296-009-1075-4, 19639319.
11. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008, 67:1516-1523. 10.1136/ard.2008.092932, 3811149, 18625622.
12. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96. 10.1136/ard.2008.105197, 3747519, 19297346.
13. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Reemus C, Rovensky J, Alecock E, Woodworth T, Alten R, OPTION Investigators Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997. 10.1016/S0140-6736(08)60453-5, 18358926, OPTION Investigators.
14. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008, 58:2968-2980. 10.1002/art.23940, 18821691.
15. Kremer JM, Blanco R, Brzosko S, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63:609-621. 10.1002/art.30158, 21360490.
16. McInnes IB, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Delles C, Sattar N. MEASURE: a translational, randomized, placebo (PBO)-controlled study to evaluate the effects of tocilizumab (TCZ) on parameters of lipids and inflammation [abstract]. Ann Rheum Dis 2011, 70((suppl)):73.
17. McInnes IB, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Delles C, Sattar N. Lipid and inflammation parameters: a translational, randomized placebo-controlled study to evaluate effects of tocilizumab: the MEASURE study 2011, Chicago, IL: Presented at: 75th Annual Scientific Meeting of the American College of Rheumatology.
18. Kobold U, Dulffer T, Dangl M, Escherich A, Kubbies M, Röddiger R, Wright JA. Quantification of hepcidin-25 in human serum by isotope dilution micro-HPLC-tandem mass spectrometry. Clin Chem 2008, 54:1584-1586. 10.1373/clinchem.2008.107029, 18755914.
19. Roy CN. Anemia of inflammation. Hematol Am Soc Hematol Educ Program 2010, 2010:276-280.